Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Details 2)

v3.20.1
Stockholders' Equity (Details 2)
3 Months Ended
Mar. 31, 2020
$ / shares
shares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Stock Options, Total Outstanding | shares 7,685,377
Stock Options, Number Exercisable | shares 4,616,153
Grant Price From 0.26 To 2.02 [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Stock Options, Grant Price, Minimum $ 0.26
Stock Options, Grant Price, Maximum 2.02
Stock Options, Weighted Average Exercise Price $ 0.90
Stock Options, Total Outstanding | shares 3,218,376
Stock Options, Number Exercisable | shares 3,029,209
Stock Options, Weighted Average Remaining Contractual Term 4 years 22 days
Grant Price From 2.40 To 4.60 [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Stock Options, Grant Price, Minimum $ 2.10
Stock Options, Grant Price, Maximum 4.60
Stock Options, Weighted Average Exercise Price $ 2.46
Stock Options, Total Outstanding | shares 3,774,001
Stock Options, Number Exercisable | shares 1,097,791
Stock Options, Weighted Average Remaining Contractual Term 8 years 5 months 9 days
Grant Price From 5.30 To 8.86 [Member]  
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Stock Options, Grant Price, Minimum $ 5.30
Stock Options, Grant Price, Maximum 8.86
Stock Options, Weighted Average Exercise Price $ 6.62
Stock Options, Total Outstanding | shares 693,000
Stock Options, Number Exercisable | shares 489,153
Stock Options, Weighted Average Remaining Contractual Term 8 years 1 month 9 days